A Retrospective Analysis of the Clinical Outcome of Inhaled Nitric Oxide (iNO) in the Neonatal Population

Background: One common therapy for hypoxic respiratory failure (HRF) in newborns is inhaled nitric oxide (iNO). The purpose of this research is to assess iNO's clinical consequences in retrospective for a set of newborns hospitalized in a 35 -bed NICU between 2010 and 2015. Methods: An examination of the 59 neonates' retrospective charts who acquired iNO for HRF has been completed. Information was collected on demographics, diagnoses, ventilator settings, dosage and duration of iNO usage, crucial signs, and 'arterial blood gas' (ABG) parameters. Patient characteristics and consequences were summarized using descriptive analysis. Gestational age was compared by employing the Mann -Whitney U test among those who survives and not. FiO2 and 'mean airway pressure' (MAP) variations earlier than and after iNO start have been measured using the Wilcoxon signed rank check. Results: 32.15 weeks (SD = 5.69) was the suggested gestational age. Congenital diaphragmatic hernia (CDH, n = 8), persistent pulmonary hypertension of the newborn (PPHN, n = 10), and respiratory distress syndrome (RDS, n = 33) have been some of the diagnoses. In 88.1% of cases (n = 52), iNO turned into an effective. Overall, 41 neonates, or 69.5% of them, survived during their hospitalization. The difference in gestational age between survivors and non -survivors is not statistically significant (p = 0.798). After beginning iNO, there have been no big variations in MAP (earlier than: 4.33±4.48vs After: 14.72±13.38;p=0.009), but there has been a better improvement in FiO2 (before: 70.88±25.82vs. After: 37.81±19.39;p=0.001).Conclusion: This research shows that iNO treatment may help newborns suffering from congestive heart failure enhance their oxygenation.To better recognize how iNO impacts longer -term outcomes and adapt treatment plans for neonatal lung disorders, similar further study is recommended.